RecruitingNCT07295340

Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection

Application of Folic Acid-Targeted Near-Infrared-II (NIR-II) Carbon Dots in Ex Vivo Histopathological Analysis of Hepatocellular Carcinoma


Sponsor

West China Hospital

Enrollment

20 participants

Start Date

Jan 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective, single-center observational study evaluates the diagnostic accuracy of a novel Folate-targeted Near-Infrared II Carbon Dot (FA-CDots) probe for the ex vivo assessment of Hepatocellular Carcinoma (HCC). Following standard radical hepatectomy, resected liver specimens will be incubated with the FA-CDots probe and imaged using a NIR-II fluorescence system. The study aims to determine the feasibility and accuracy of this technology in identifying tumor margins and micro-lesions by comparing the fluorescence imaging results with standard histopathological examination.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria6

  • Primary diagnosis of Hepatocellular Carcinoma (HCC) confirmed clinically or by preoperative biopsy.
  • Scheduled for radical hepatectomy.
  • Preoperative imaging (CT/MRI) suggests indistinct tumor boundaries, infiltrative growth, or proximity to major vessels (expected margin \< 1cm).
  • Liver function classified as Child-Pugh Grade A.
  • ASA Physical Status classification I-III.
  • Participant or legal guardian willing to sign informed consent for the use of ex vivo tissues.

Exclusion Criteria6

  • Concomitant other malignant tumors.
  • Severe dysfunction of heart, lung, kidney, or brain unable to tolerate surgery.
  • Recurrent HCC.
  • Preoperative evidence of extrahepatic metastasis or major vascular invasion.
  • Received preoperative anti-tumor therapy.
  • Pregnant or lactating women.

Interventions

DIAGNOSTIC_TESTEx Vivo FA-CDots Staining

The resected liver specimens are incubated with Folate-targeted Near-Infrared II Carbon Dots (FA-CDots) and imaged using a NIR-II fluorescence imaging system to identify tumor margins and micro-lesions. The results are compared with standard histopathology.


Locations(1)

West China Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07295340


Related Trials